[go: up one dir, main page]

WO2000070099A3 - Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives - Google Patents

Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives Download PDF

Info

Publication number
WO2000070099A3
WO2000070099A3 PCT/US2000/013951 US0013951W WO0070099A3 WO 2000070099 A3 WO2000070099 A3 WO 2000070099A3 US 0013951 W US0013951 W US 0013951W WO 0070099 A3 WO0070099 A3 WO 0070099A3
Authority
WO
WIPO (PCT)
Prior art keywords
contactin
present
neurodegenerative disease
compounds
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/013951
Other languages
English (en)
Other versions
WO2000070099A2 (fr
Inventor
Jung-Joo Hwang
K David Becker
Robert E Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Migenix Corp
Original Assignee
Mitokor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokor Inc filed Critical Mitokor Inc
Priority to EP00936142A priority Critical patent/EP1208228A2/fr
Priority to JP2000618504A priority patent/JP2003504007A/ja
Priority to AU51503/00A priority patent/AU5150300A/en
Priority to CA002371212A priority patent/CA2371212A1/fr
Publication of WO2000070099A2 publication Critical patent/WO2000070099A2/fr
Anticipated expiration legal-status Critical
Publication of WO2000070099A3 publication Critical patent/WO2000070099A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L"invention concerne des molécules d"acide nucléique fonctionnant en tant qu"amorces de réaction PCR, dans la détection d"ARNm contactine, dans un échantillon. Il est possible de marquer ces molécules d"acide nucléique et de les préparer dans une trousse. L"invention concerne également un procédé de détection d"une maladie neurodégénérative, telle que la sclérose en plaques, ce procédé consistant à prélever un échantillon sur un patient, et à mesurer la quantité de protéine contactine ou d"ARNm contactine exprimée dans l"échantillon. L"invention concerne encore un procédé d"identification de patients souffrant d"une maladie neurodégénérative et susceptibles de répondre au traitement d"une telle maladie, de même que des compositions de matière comprenant une cellule isolée ou une cellule placée dans un culture qui exprime une quantité accrue ou diminuée de contactine par rapport à une cellule témoin. L"invention concerne aussi un procédé de criblage de composés, servant à mettre en évidence leur activité de réduction ou d"augmentation de l"expression de la contactine, ainsi que des compositions ou composés, notamment des compositions pharmaceutiques, identifiés à l"aide de ce procédé. On décrit encore des méthodes de traitement d"une maladie neurodégénérative à l"aide de tels composés ou compositions, ainsi que des procédés d"identification de cibles pharmaceutiques destinées à des composés modulant l"expression ou l"activité de la contactine, ainsi que des cibles identifiées à l"aide de tels procédés.
PCT/US2000/013951 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives Ceased WO2000070099A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00936142A EP1208228A2 (fr) 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives
JP2000618504A JP2003504007A (ja) 1999-05-19 2000-05-19 神経変性性疾患における脳の特異的な領域での異なる遺伝子発現
AU51503/00A AU5150300A (en) 1999-05-19 2000-05-19 Differential gene expression in specific regions of the brain in neurodegenerative diseases
CA002371212A CA2371212A1 (fr) 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13479099P 1999-05-19 1999-05-19
US60/134,790 1999-05-19
US57461300A 2000-05-18 2000-05-18
US09/574,613 2000-05-18

Publications (2)

Publication Number Publication Date
WO2000070099A2 WO2000070099A2 (fr) 2000-11-23
WO2000070099A3 true WO2000070099A3 (fr) 2002-04-04

Family

ID=26832668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013951 Ceased WO2000070099A2 (fr) 1999-05-19 2000-05-19 Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives

Country Status (5)

Country Link
EP (1) EP1208228A2 (fr)
JP (1) JP2003504007A (fr)
AU (1) AU5150300A (fr)
CA (1) CA2371212A1 (fr)
WO (1) WO2000070099A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001240820A1 (en) * 2000-03-15 2001-09-24 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular dementia
WO2002040996A2 (fr) * 2000-11-08 2002-05-23 Mitokor Expression genetique differentielle dans des regions specifiques du cerveau dans les maladies neurodegeneratives
CN1549721B (zh) 2001-02-27 2012-03-07 布朗歇特洛克菲勒神经科学研究所 基于促分裂原活化的蛋白激酶的磷酸化诊断阿尔茨海默氏病
WO2003023056A2 (fr) * 2001-09-12 2003-03-20 F. Hoffmann-La Roche Ag Marqueurs specifiques a la sclerose en plaques
ATE449964T1 (de) * 2002-04-24 2009-12-15 Evotec Neurosciences Gmbh DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
EP1587960A2 (fr) * 2003-01-30 2005-10-26 Research Development Foundation Procedes et compositions d'analyse de l'expression genique liee a la mitochondrie
JP2008520203A (ja) * 2004-11-15 2008-06-19 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病の診断および治療のためのホスファターゼ２ａ（ｐｐ２ａ）の異常
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
US8252540B2 (en) 2007-08-03 2012-08-28 Keio University Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesion
WO2010014585A1 (fr) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Composés d'activation de pkc utiles dans le traitement de maladies neurodégénératives
JP2011529344A (ja) 2008-07-28 2011-12-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病の刺激誘発ゲノムプロフィールマーカー
US8658134B2 (en) 2009-10-02 2014-02-25 Blanchette Rockefeller Neurosciences Institute Fibroblast growth patterns for diagnosis of Alzheimer's disease
CA2856235A1 (fr) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Esters de dcpla pour le traitement de troubles neurodegeneratifs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035373A2 (fr) * 1994-06-10 1995-12-28 La Jolla Cancer Research Foundation Molecules d'acide nucleique codant la contactine humaine
WO1997015690A1 (fr) * 1995-10-24 1997-05-01 Curagen Corporation Procede et dispositif d'identification, de classification ou de denombrement de sequences d'adn dans un echantillon sans sequençage
US5739289A (en) * 1993-03-26 1998-04-14 Becton, Dickinson And Company Monoclonal antibody to human cell adhesion molecule
WO1998049342A1 (fr) * 1997-04-30 1998-11-05 Forskningsparken I Ås As Procede servant a preparer un type standard de produit de transcription genetique de diagnostic
US5888498A (en) * 1995-03-03 1999-03-30 Mitokor Cellular and animal models for diseases associated with mitochondrial defects

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739289A (en) * 1993-03-26 1998-04-14 Becton, Dickinson And Company Monoclonal antibody to human cell adhesion molecule
WO1995035373A2 (fr) * 1994-06-10 1995-12-28 La Jolla Cancer Research Foundation Molecules d'acide nucleique codant la contactine humaine
US5888498A (en) * 1995-03-03 1999-03-30 Mitokor Cellular and animal models for diseases associated with mitochondrial defects
WO1997015690A1 (fr) * 1995-10-24 1997-05-01 Curagen Corporation Procede et dispositif d'identification, de classification ou de denombrement de sequences d'adn dans un echantillon sans sequençage
WO1998049342A1 (fr) * 1997-04-30 1998-11-05 Forskningsparken I Ås As Procede servant a preparer un type standard de produit de transcription genetique de diagnostic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLAGGE A ET AL: "The gene of the neural cell recognition molecule F11: conserved exon-intron arrangement in genes of neural members of the immunoglobulin superfamily", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 192, no. 2, 1997, pages 215 - 225, XP004081714, ISSN: 0378-1119 *
SHIMAZAKI K ET AL: "Age-related decline of f3/contactin in rat hippocampus", NEUROSCIENCE LETTERS, vol. 245, no. 2, 1998, pages 117 - 20, XP001024403 *

Also Published As

Publication number Publication date
AU5150300A (en) 2000-12-05
JP2003504007A (ja) 2003-02-04
EP1208228A2 (fr) 2002-05-29
WO2000070099A2 (fr) 2000-11-23
CA2371212A1 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
Condliffe et al. Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain
Nakano et al. Homologous recombination but not nucleotide excision repair plays a pivotal role in tolerance of DNA-protein cross-links in mammalian cells
Li et al. Senescent immune cells release grancalcin to promote skeletal aging
Kwong et al. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease
Haghdoost et al. The nucleotide pool is a significant target for oxidative stress
Goto et al. Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknotting, and relaxation of double-stranded DNA rings.
Lu et al. DNA methylation, a hand behind neurodegenerative diseases
Zhu et al. MicroRNA-494 improves functional recovery and inhibits apoptosis by modulating PTEN/AKT/mTOR pathway in rats after spinal cord injury
US10550426B2 (en) Method for detecting methylated DNA
CN110791560B (zh) 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物
WO2000070099A3 (fr) Expression genique differente dans des regions specifiques du cerveau, dans des maladies neurodegeneratives
Kumar et al. Tet1 oxidase regulates neuronal gene transcription, active DNA hydroxymethylation, object location memory, and threat recognition memory
Li et al. Nuclear respiratory factor 1 (NRF-1) controls the activity dependent transcription of the GABA-A receptor beta 1 subunit gene in neurons
Sarasin et al. New insights for understanding the transcription-coupled repair pathway
Gao et al. Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel
Rezende et al. Knock out of the NADPH oxidase Nox4 has no impact on life span in mice
Guo et al. Genome-wide antagonism between 5-hydroxymethylcytosine and DNA methylation in the adult mouse brain
WO2010011283A3 (fr) Composés à base de fus/tls et méthodes de diagnostic, traitement et prévention d'une sclérose latérale amyotrophique et de maladies des motoneurones apparentées
Mukai et al. Recombinant mammalian tubulin polyglutamylase TTLL7 performs both initiation and elongation of polyglutamylation on β-tubulin through a random sequential pathway
WO2006096737A3 (fr) Cible diagnostique et therapeutique pour degenerescence maculaire
AU2016282350A1 (en) Targeted enrichment of long nucleotide sequences using microfluidic partitioning
Jensen et al. Human calmodulin mutations cause arrhythmia and affect neuronal function in C. elegans
Rybin et al. Emerging technologies for genome-wide profiling of DNA breakage
JP2010535501A (ja) チオプリン薬抵抗性およびチオプリン薬不耐性のリスクがある個体を同定する方法
Vindry et al. A homozygous mutation in the human selenocysteine tRNA gene impairs UGA recoding activity and selenoproteome regulation by selenium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371212

Country of ref document: CA

Ref country code: CA

Ref document number: 2371212

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 51503/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 618504

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000936142

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000936142

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000936142

Country of ref document: EP